Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | STK17B | O94768 | 1/20 | 0.37 |
| ▸ | STK17A | Q9UEE5 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 7/20 | 0.36 |
| ▸ | CA2 | P00918 | 7/20 | 0.36 |
| ▸ | CA12 | O43570 | 4/20 | 0.36 |
| ▸ | CA9 | Q16790 | 4/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3965164 | 0.94 | HTR2A (0.38) | DRD2STK17BSTK17ACA1CA2 | |
| Cadaverine Tartrate SCHEMBL4960583 | 0.88 | GBA1 (0.35) | DRD2STK17BSTK17ACA1CA2 | |
| SCHEMBL3961645 | 0.81 | HTR2A (0.40) | DRD2HTR2AHTR2CHTR2B | |
| SCHEMBL14115742 | 0.79 | LMNA (0.42) | DRD2STK17BSTK17ACA1CA2 | |
| SCHEMBL3970643 | 0.75 | HTR2A (0.41) | HTR2AHTR2CHTR2BGAA | |
| SCHEMBL3965049 | 0.74 | HTR2A (0.38) | HTR2AHTR2CHTR2BMEN1KMT2A | |
| SCHEMBL3966305 | 0.69 | HTR2A (0.39) | HTR2AHTR2CHTR2B | |
| SCHEMBL14115779 | 0.68 | POLB (0.43) | DRD2HTR2AHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL506762 | 0.67 | HTR2A (0.39) | HTR2AHTR2CHTR2BKMT2A | |
| SCHEMBL27140548 | 0.65 | DRD2 (0.39) | DRD2METAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420631-B2 | Serotonin receptor antagonist; therapy for obesity, antidepressants, obsessive-compulsive disorders | ELI LILLY AND COMPANY (US) | 2013-04-16 | — | — | US | disclosed |
| EP-1926712-B1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | LILLY CO ELI (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | ELI LILLY AND COMPANY | 2008-08-28 | — | — | US | disclosed |
| WO-2007028131-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207897-A1 | 6-Substituted-2,3,4,5-Tetrahydro-1H-Benzo[D] Azepines as 5-Ht2c Receptro Agonists | HTR2C, HTR2A, HTR1A | DRD2 21/4885STK17B 3718/4885STK17A 3357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.